Graft Versus Host Disease Market By Product Type, By Treatment Type, By End Use : Global Opportunity Analysis and Industry Forecast, 2021-2031

List of Tables

The global Graft Versus Host Disease Market was valued at $2,968.6 million in 2021, and is projected to reach $10,375.3 million by 2031, registering a CAGR of 13.5% from 2022 to 2031.

Graft versus host disease (GVHD) is a condition that might occur after an allogeneic transplant (bone marrow transplant). In GVHD, the donated bone marrow or peripheral blood stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body. There are two forms of GVHD: acute graft versus host disease (aGVHD) and chronic graft versus host disease (cGVHD).

The pathophysiology of aGVHD and cGVHD remains incompletely understood. One commonly quoted model suggests three distinct stages in the development of aGVHD: a conditioning regimen, which damages host tissues, including intestinal mucosa and liver; activation of donor T cells against host antigens & subsequent clonal T-cell expansion; and release of inflammatory cytokines such as interleukin 1 (IL-1) & tumor necrosis factor (TNFα), leading to further host tissue damage. Several mechanisms have been implicated in cGVHD pathogenesis, including persistence of donor-derived alloreactive T cells, autoreactive T cells, B cells producing antibodies against the host, and mechanisms of chronic inflammation leading to end organ fibrosis.

Despite decades of research and improvements in post-transplant immunosuppressive therapies, graft-versus-host disease (GVHD) remains a significant cause of morbidity and mortality in allogenic hematopoietic stem-cell transplant (HSCT) recipients.

The COVID-19 pandemic has had an impact on a variety of businesses around the world. The Graft Versus Host Disease Market had a significant impact as well. To halt the spread of COVID-19, governments around the world implemented harsh restrictions such as border locks, lockdowns, and tight social distancing measures. These measures had a significant impact on the global economy, affecting a variety of industries. Pharmaceutical and biotech companies together with governments around the globe work to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline.

Impact of COVID-19: The COVID-19 pandemic has significantly changed the landscape of kidney transplantation in the U.S. and worldwide. In addition to adversely impacting allograft and patient survival in post kidney transplant recipients, the current pandemic has affected all aspects of transplant care, including transplant referrals and listing, organ donation rates, organ procurement and shipping, and waitlist mortality.

As kidney transplantation rates declined, so did organ procurement rates. The UK reported a 39% decrease in referrals of organs to OPOs. France reported a 16% decrease in all deceased organ procurement rates as compared to previous years. Part of these declines were due to procurement challenges faced by transplant programs and organizations, such as insufficient testing capabilities and delayed COVID-19 test results, limited operating room availabilities, and mandates for the avoidance of nonessential clinical activities to preserve personnel and protective equipment.

Therefore, the overall impact of COVID-19 remains negative on graft versus host disease market due to decline in number of transplantation procedure. The transplant procedure requires the routine use of reusable equipment with close contact with patients. This increases the risk of disease transmission.

Increase in number of grafts versus host disease, which arises predominantly due to rise in number of allogenic transplantations. Also, increase in disease diagnosis rate and increase in number of products available for the treatment of graft versus host disease are the factors fueling the growth of the market.

According to preliminary data from the Organ Procurement and Transplantation Network, in 2020 organ donation from deceased donors in the U.S. set an all-time record. A total of 12,587 people provided one or more organs to save and enhance the lives of others, representing an increase of six percent over 2019.

Moreover, much of the increase in deceased donation was made possible by donors representing less traditional medical criteria. The most common age range of deceased donors was 50 to 64. The 3,726 donors in this category increased by 7.9 percent over 2019. Donation increased significantly among individuals who died of cardiorespiratory failure as opposed to brain death; the 3,223 donors after cardiorespiratory death (DCD donors) increased by 18.6 percent over the total in 2019.

According to Organ Donation Statistics, 105,988 number of men, women, and children are on the national transplant waiting list, whereas 17 people die each day waiting for the organ transplant and an estimated 40,000 transplants were performed in 2021.

Complications such as allergic reactions, which cannot be detected by computational biology and other post-surgery complications, unfavorable government scenario, the high initial cost and maintenance costs of the instruments, lack of standardization, and shortage of skilled workforce are expected to be the significant restraints to market growth during the forecast period.

The graft versus host disease market is segmented on the basis of product, diagnosis, types, end use, and region. By product the market is segmented into corticosteroids, monoclonal antibodies, immunosuppressants and others. On the basis of type the segment is divided into acute and chronic. On the basis of end use the segment is divided into hospital pharmacies, retail pharmacies and online pharmacies.

Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the graft versus host disease market are AbbVie, Asahi Kasei, Bristol Myer Squibb, GlaxoSmithKline, Incyte Corporation, Medac GmbH, Merck & co., Novartis, Pfizer and Sanofi.

Key Benefits For Stakeholders

The study provides an in-depth analysis of the graft versus host disease market, and the current graft versus host disease market trends and future estimations to elucidate imminent investment pockets.

It presents a quantitative analysis of the market from 2022 to 2031 to enable stakeholders to capitalize on the prevailing market graft versus host disease market opportunity.

Extensive analysis of the market based on procedures and services assists to understand the trends in the graft versus host disease industry.

Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

Key Market Segments

By Product Type

Corticosteroids
Monoclonal antibodies
Immunosuppressants
Others

By Treatment Type

Acute GVHD
Chronic GVHD

By End Use

Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Turkey
- South Africa
- Rest of LAMEA
Key Market Players
- Sanofi
- Novartis AG
- Merck & Co.
- Abbvie Inc
- Pfizer Inc.
- Accord Healthcare Limited
- Bristol Myer Squibb
- Asahi Kasei Corporation
- Glaxosmithkline plc
- Incyte Corporation

Product Code: A11929

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Corticosteroids
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
4.3 Monoclonal antibodies
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
4.4 Immunosuppressants
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
4.5 Others
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country

CHAPTER 5: GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Acute GVHD
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
5.3 Chronic GVHD
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country

CHAPTER 6: GRAFT VERSUS HOST DISEASE MARKET, BY END USE

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Hospitals Pharmacies
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
6.3 Retail Pharmacies
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
6.4 Online Pharmacies
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country

CHAPTER 7: GRAFT VERSUS HOST DISEASE MARKET, BY REGION

7.1 Overview
- 7.1.1 Market size and forecast
7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Product Type
- 7.2.3 North America Market size and forecast, by Treatment Type
- 7.2.4 North America Market size and forecast, by End Use
- 7.2.5 North America Market size and forecast, by country
  - 7.2.5.1 U.S.
  - 7.2.5.1.1 Market size and forecast, by Product Type
  - 7.2.5.1.2 Market size and forecast, by Treatment Type
  - 7.2.5.1.3 Market size and forecast, by End Use
  - 7.2.5.2 Canada
  - 7.2.5.2.1 Market size and forecast, by Product Type
  - 7.2.5.2.2 Market size and forecast, by Treatment Type
  - 7.2.5.2.3 Market size and forecast, by End Use
  - 7.2.5.3 Mexico
  - 7.2.5.3.1 Market size and forecast, by Product Type
  - 7.2.5.3.2 Market size and forecast, by Treatment Type
  - 7.2.5.3.3 Market size and forecast, by End Use
7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Product Type
- 7.3.3 Europe Market size and forecast, by Treatment Type
- 7.3.4 Europe Market size and forecast, by End Use
- 7.3.5 Europe Market size and forecast, by country
  - 7.3.5.1 Germany
  - 7.3.5.1.1 Market size and forecast, by Product Type
  - 7.3.5.1.2 Market size and forecast, by Treatment Type
  - 7.3.5.1.3 Market size and forecast, by End Use
  - 7.3.5.2 France
  - 7.3.5.2.1 Market size and forecast, by Product Type
  - 7.3.5.2.2 Market size and forecast, by Treatment Type
  - 7.3.5.2.3 Market size and forecast, by End Use
  - 7.3.5.3 United Kingdom
  - 7.3.5.3.1 Market size and forecast, by Product Type
  - 7.3.5.3.2 Market size and forecast, by Treatment Type
  - 7.3.5.3.3 Market size and forecast, by End Use
  - 7.3.5.4 Italy
  - 7.3.5.4.1 Market size and forecast, by Product Type
  - 7.3.5.4.2 Market size and forecast, by Treatment Type
  - 7.3.5.4.3 Market size and forecast, by End Use
  - 7.3.5.5 Spain
  - 7.3.5.5.1 Market size and forecast, by Product Type
  - 7.3.5.5.2 Market size and forecast, by Treatment Type
  - 7.3.5.5.3 Market size and forecast, by End Use
  - 7.3.5.6 Rest of Europe
  - 7.3.5.6.1 Market size and forecast, by Product Type
  - 7.3.5.6.2 Market size and forecast, by Treatment Type
  - 7.3.5.6.3 Market size and forecast, by End Use
7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Product Type
- 7.4.3 Asia-Pacific Market size and forecast, by Treatment Type
- 7.4.4 Asia-Pacific Market size and forecast, by End Use
- 7.4.5 Asia-Pacific Market size and forecast, by country
  - 7.4.5.1 Japan
  - 7.4.5.1.1 Market size and forecast, by Product Type
  - 7.4.5.1.2 Market size and forecast, by Treatment Type
  - 7.4.5.1.3 Market size and forecast, by End Use
  - 7.4.5.2 China
  - 7.4.5.2.1 Market size and forecast, by Product Type
  - 7.4.5.2.2 Market size and forecast, by Treatment Type
  - 7.4.5.2.3 Market size and forecast, by End Use
  - 7.4.5.3 Australia
  - 7.4.5.3.1 Market size and forecast, by Product Type
  - 7.4.5.3.2 Market size and forecast, by Treatment Type
  - 7.4.5.3.3 Market size and forecast, by End Use
  - 7.4.5.4 India
  - 7.4.5.4.1 Market size and forecast, by Product Type
  - 7.4.5.4.2 Market size and forecast, by Treatment Type
  - 7.4.5.4.3 Market size and forecast, by End Use
  - 7.4.5.5 South Korea
  - 7.4.5.5.1 Market size and forecast, by Product Type
  - 7.4.5.5.2 Market size and forecast, by Treatment Type
  - 7.4.5.5.3 Market size and forecast, by End Use
  - 7.4.5.6 Rest of Asia-Pacific
  - 7.4.5.6.1 Market size and forecast, by Product Type
  - 7.4.5.6.2 Market size and forecast, by Treatment Type
  - 7.4.5.6.3 Market size and forecast, by End Use
7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Product Type
- 7.5.3 LAMEA Market size and forecast, by Treatment Type
- 7.5.4 LAMEA Market size and forecast, by End Use
- 7.5.5 LAMEA Market size and forecast, by country
  - 7.5.5.1 Brazil
  - 7.5.5.1.1 Market size and forecast, by Product Type
  - 7.5.5.1.2 Market size and forecast, by Treatment Type
  - 7.5.5.1.3 Market size and forecast, by End Use
  - 7.5.5.2 Turkey
  - 7.5.5.2.1 Market size and forecast, by Product Type
  - 7.5.5.2.2 Market size and forecast, by Treatment Type
  - 7.5.5.2.3 Market size and forecast, by End Use
  - 7.5.5.3 South Africa
  - 7.5.5.3.1 Market size and forecast, by Product Type
  - 7.5.5.3.2 Market size and forecast, by Treatment Type
  - 7.5.5.3.3 Market size and forecast, by End Use
  - 7.5.5.4 Rest of LAMEA
  - 7.5.5.4.1 Market size and forecast, by Product Type
  - 7.5.5.4.2 Market size and forecast, by Treatment Type
  - 7.5.5.4.3 Market size and forecast, by End Use

CHAPTER 8: COMPANY LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES

9.1 Sanofi
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
9.2 Novartis AG
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
9.3 Merck & Co.
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
9.4 Abbvie Inc
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
9.5 Pfizer Inc.
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
9.6 Accord Healthcare Limited
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
9.7 Bristol Myer Squibb
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
9.8 Asahi Kasei Corporation
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
9.9 Glaxosmithkline plc
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
9.10 Incyte Corporation
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments